PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Pfizer/BioNTech vaccine effective against Omicron in children five and under

Companies say that a three-dose vaccine for children aged six months to five years old is 80% effective at preventing illness.

According to recent clinical trial results from Pfizer and BioNTech, a third COVID-19 vaccine dose was well tolerated by children aged five and below, and most side effects were mild-to-moderate.

The companies say that their three-dose vaccine for children aged six months to five years old was 80% effective at preventing illness during the surge of the Omicron variant.

Pfizer and BioNTech plan to complete their application for the US Food and Drug Administration (FDA) to authorise the vaccine this week, according to BioNTech CEO, Ugur Sahin.

The clinical trial data includes 1,678 children under five who received the third shot at least two months after their second dose while Omicron was the main variant. During the Omicron surge, kids aged five years or younger were hospitalised with COVID-19 at five times the rate of the pandemic peak, according to the Centers for Disease Control and Prevention (CDC).

Kids under the age of five receive 3-microgram shots, which is one-tenth the dosage of adults. They are the only age cohort in the US that remains ineligible for vaccination.

Pfizer had initially planned to seek fast-track authorisation from the FDA earlier this year, while clinical trial results were still pending. This was delayed, however, in order to wait on data from the third dose after the first two shots were only 30% to 40% effective.

An FDA committee of independent vaccine experts is expected to meet in June regarding Pfizer’s application, as well as one from fellow vaccine manufacturer Moderna to authorise its two-dose vaccine for children under age six. Current dates have been set for 8, 21 and 22 June, according to media reports.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026